Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible …

DNA methylation and histone modification are epigenetic mechanisms that result in altered
gene expression and cellular phenotype. The exact role of methylation in myelodysplastic …

Resistance to the hypomethylating agents (HMAs) 5-azacytidine (AZA) and 5-aza-2′-
deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with …

Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for
myelodysplastic syndrome (MDS). Response to these agents occurs in∼ 50% of treated …

The term epigenetics refers to the heritable changes in gene expression that are not
associated with a change in the actual DNA sequence. Epigenetic dysregulation is linked to …

Aberrant DNA methylation is a critically important modification in cancer cells, which,
through promoter and enhancer DNA methylation changes, use this mechanism to activate …

Although the first studies using DNA demethylating agents at low doses in hematologic
neoplasia and hemoglobinopathies were initiated more than 20 years ago, development of …

BACKGROUND AND OBJECTIVES: Methylation of DNA is a common epigenetic
modification that plays an important role in the control of gene expression in mammalian …

A variety of epigenetic changes contribute to transcriptional dysregulation in myelodysplastic
syndromes (MDSs) and acute myeloid leukemia (AML). DNA methyltransferase (DNMT) …